Tectonic Therapeutic, INC Form 4 insider transactions

Peter McNamara, Chief Scientific Officer of Tectonic Therapeutic, exercised stock options to acquire 3,500 shares of common stock.

Director Timothy Springer purchased 300,000 shares of Tectonic Therapeutic at $33.59 per share, increasing his direct holdings to 4,096,764 shares.

Director Timothy Springer reports acquiring and disposing of Tectonic Therapeutic shares through a distribution in kind and open market purchases.

Following the merger of AVROBIO and Tectonic, Braden Michael Leonard reports acquiring shares of Tectonic Therapeutic, Inc. due to the merger agreement.

Director Phillip Donenberg of Tectonic Therapeutic, Inc. reports the acquisition of stock options.

Stefan Vitorovic, a director of Tectonic Therapeutic, reports acquiring shares and stock options as a result of the merger between AVROBIO and Tectonic, along with indirect ownership through Vida Ventures LLCs.

Director Praveen P. Tipirneni reports changes in beneficial ownership of Tectonic Therapeutic securities following the merger with AVROBIO, including acquisition and disposal of common stock and stock options.

Director Timothy A. Springer reports acquiring shares and stock options in Tectonic Therapeutic following the merger with AVROBIO, Inc.

Director Terrance McGuire reports acquisition of common stock and stock options in Tectonic Therapeutic following the merger with AVROBIO, reflecting adjustments from the merger agreement.

Marc Schwabish, Chief Business Officer of Tectonic Therapeutic, reports the acquisition of stock options following the merger, as detailed in a Form 4 filing with the SEC.

Chief Medical Officer of Tectonic Therapeutic, Marcella K. Ruddy, reports acquisition of shares and stock options following the merger with AVROBIO, Inc.

Peter McNamara, Chief Scientific Officer of Tectonic Therapeutic, reports the acquisition of common stock and stock options following the merger with AVROBIO, Inc.

Daniel Lochner, CFO of Tectonic Therapeutic, Inc., reports the acquisition of 118,000 employee stock options.

Christian Cortis, Chief Operating Officer of Tectonic Therapeutic, reports the acquisition and conversion of common stock and stock options following the merger with AVROBIO, Inc.

Alise Reicin, CEO of Tectonic Therapeutic, reports the acquisition of common stock and stock options following the merger with AVROBIO, Inc.

AVROBIO, Inc. is supplementing disclosures related to its merger with Tectonic Therapeutic, Inc. to address stockholder lawsuits and demands alleging misrepresentations and omissions in the registration statement.

Tectonic Therapeutic appoints Daniel Lochner as Chief Financial Officer, effective June 3, 2024, in anticipation of the merger with AVROBIO.

AVROBIO is urging its shareholders to vote in favor of the proposed merger with Tectonic Therapeutic at the upcoming Special Meeting on June 11th.

AVROBIO is urging its shareholders to vote in favor of the proposed merger with Tectonic Therapeutic at the upcoming Special Meeting of Stockholders on June 11, 2024.

Braden Michael Leonard, a director and 10% owner of AVROBIO, Inc., has increased his indirect holdings through purchases made by BML Investment Partners, L.P.

AVROBIO and Tectonic Therapeutic are set to merge, backed by a $130.7 million private financing, to focus on developing novel GPCR-targeted therapies with a cash runway into mid-2027.